TD-0212 TFA is an orally active dual pharmacology angiotensin II type 1 receptor (AT 1 ) antagonist and neprilysin (NEP) inhibitor, with a pK i of 8.9 for AT 1 and a pIC 50 of 9.2 for NEP
In Vitro
TD-0212 provides the enhanced activity of dual AT1/NEP inhibition with a potentially lower risk of angioedema relative to dual ACE/NEP inhibition. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
TD-0212 produces blood pressure reductions similar to omapatrilat and combinations of AT1 receptor antagonists and NEP inhibitors in models of renin-dependent and -independent hypertension . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
